On July 14, Intuitive Surgical fell 3.04% in regular trading, trading at $388.97/share, with turnover of $175 million. The decline came as multiple investment banks lowered their price targets ahead of the company's upcoming earnings report.

On July 13, BTIG Research cut its price target on Intuitive Surgical to $512 from $574 while maintaining a Buy rating, and Royal Bank of Canada lowered its target to $600 from $650, keeping an Outperform rating. The consensus mean price target now stands at $563.36 according to FactSet. This follows earlier cuts from Evercore ISI (to $430 from $480) and Goldman Sachs (to $558 from $621) in recent months.

The broader Health Care Equipment sector faced significant selling pressure on the same day. Stryker fell 5.95%, GE Healthcare declined 4.95%, Boston Scientific dropped 4.38%, Medtronic lost 4.13%, and Abbott Laboratories slid 3.30%. BMO Capital Markets has attributed recent sector weakness to capital rotation toward AI rather than fundamental deterioration. The company's next earnings report is scheduled for July 16 after market close, contributing to elevated caution among investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)